Josep M. Llovet

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Life & Medical Sciences

Josep M. Llovet, MD is ICREA Research Professor, BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, Univ. of Barcelona, Prof. of Medicine and Director of the Liver Cancer Program at the Icahn Mount Sinai School of Medicine, NY. He has published 242 manuscripts in Liver Cancer, including NEJM, Lancet, Nature, Nat. Genetics, Cancer Cell and Gastroenterology (IF: 3262;citations: 44.256;h-index: 85). Top 1% most cited researcher globally, Thomson Reuters 2014, 2015, 2016, Educational Councilor (2013-15), President of the ILCA (2011-13), Senior Editor of CCR, he has lectured in 500 international meetings and has been the PI of European grants FP7-HEPTROMIC,HEP-CAR,NIH-NIDDK R01-award, I+D grants and competitive private grants. His achievements are: 1. Establish a clinical and molecular classification for HCC. 2. Establish efficacy of chemoembolization and sorafenib for HCC. 3. Identification of novel drivers and activated pathways in HCC and ICC.

Research interests

Prof Josep M. Llovet has been working in clinical and translational research in hepatocellular carcinoma (HCC) and cholangiocarcinoma (ICC) for the last 20 years .He is leading international randomized trials in HCC on novel targeted therapies and developing a molecular classification of the disease,understanding the genetic aberrations and signaling pathways involved and in the identification of new molecular targeted therapies. He has organized the HCC Genomic Consortium and the HEPTROMIC Consortium (funded by an FP-7 Grant) that includes several international HCC research centers: IDIBAPS-Hospital Clínic (Barcelona), Ichan Scool of Medicine at Mount Sinai (New York), INSERM (Paris), Univ. Tuebingen (Germany), Dana-Farber-MIT-Broad Institute (Boston) and NCI (Milan).The main future areas of interest are a) identify biomarkers predicting response to sorafenib or mechanisms of resistance b) translate oncogenic drivers discoveries as targeted therapies in HCC and ICC.

Selected publications

– Martinez-Quetglas I, Pinyol R, Dauch D et al. 2016, ‘IGF2 Is Up-regulated by …’, Gastroenterology, vol.62, no. 2, pp. S405–S406.

– Moran S, Martínez-Cardús A, Sayols S et al. 2016, ‘Epigenetic profiling to …’, Lancet Oncol., vol. 17, no.10, pp. 1386-1395.

– Lencioni R, Llovet JM, Han G et al. 2016, ‘Sorafenib or placebo plu…’, J. Hepatol., vol.64, no.5, pp. 1090-1098.

– Villanueva A & Llovet JM 2016, ‘Liver cancer: Effect of HCV …’, (Editorial), Nature Reviews Gastroenterol and Hepatol, vol.13, no.10, pp. 561-562.

Llovet JM 2016, ‘Handbook of Translational Medicine’, Edicions de la Universitat de Barcelona, Barcelona-B, 16.985-2016.

– Torrens L, Pinyol R, Jimenez W et al. 2016, ‘Oveview of Translational Medicine’, In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B, 16.985-2016.

– Moeini A, Sia D, Bardeesy N et al. 2016, ‘Molecular Pathogenesis …’, Clin Cancer Res. vol.22, no.2, pp 291-300.

– Montal R, Torres F & Llovet JM 2016, ‘The design of clinical trials in the genomic era’, In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B, 16.985-2016.

– Zhang DY, Goossens N, Guo J et al. 2016, ‘A hepatic stellate cell gene…’, Gut., vol. 65, no.10, pp. 1754-1764.

Llovet JM, Zucman-Rossi J, Pikarsky E et al. 2016, ‘Hepatocellular carcinoma’, Nat. Rev. Dis. Primers, no.2, pp. 16018.

– Nakagawa S, Wei L, Song WM et al. 2016, ‘Precision Liver Cancer Prevention Consortium’, ‘Molecular Liver Cancer Prevention …’, Cancer Cell, vol. 30, no. 6, pp. 879-890.

Selected research activities

Senior Editor. Clinical Cancer Research / Director. Master in Translational Medicine. Universitat de Barcelona / Executive Committee. IDIBAPS / Director. Liver Cancer Program. Icahn School of Medicine at Mount Sinai / Fellow Award – American Association for the Study of the Liver Diseases (AALSD) / Tisch Cancer Institute Award – NCI designated Cancer Center Recognition ISMMS.